Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer
- PMID: 17293390
- PMCID: PMC1972421
- DOI: 10.1136/jcp.2006.043356
Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer
Conflict of interest statement
Competing interests: none declared.
References
-
- Slamon D J, Leyland‐Jones B, Shak S.et al Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001344783–792. - PubMed
-
- Saez A, Andreu F A, Segui M A.et al HER‐2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer—a study of two hundred cases. Breast 200615519–527. - PubMed
-
- Pauletti G, Dandekar S, Rong H.et al Assessment of methods for tissue‐based detection of the HER‐2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000183651–3664. - PubMed
-
- Gong Y, Gilcrease M, Sneige N. Reliability of chromogenic in situ hybridization for detecting HER‐2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility. Mod Pathol 2005181015–1021. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous